Grail Inc
NASDAQ:GRAL

Watchlist Manager
Grail Inc Logo
Grail Inc
NASDAQ:GRAL
Watchlist
Price: 100.98 USD -3.56% Market Closed
Market Cap: 3.9B USD

Grail Inc
Other Long-Term Assets

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Grail Inc
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Grail Inc
NASDAQ:GRAL
Other Long-Term Assets
$11.1m
CAGR 3-Years
16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Long-Term Assets
$9.6B
CAGR 3-Years
21%
CAGR 5-Years
20%
CAGR 10-Years
23%
Gilead Sciences Inc
NASDAQ:GILD
Other Long-Term Assets
$7.9B
CAGR 3-Years
20%
CAGR 5-Years
6%
CAGR 10-Years
18%
Amgen Inc
NASDAQ:AMGN
Other Long-Term Assets
$13.2B
CAGR 3-Years
28%
CAGR 5-Years
20%
CAGR 10-Years
22%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Long-Term Assets
$4B
CAGR 3-Years
50%
CAGR 5-Years
22%
CAGR 10-Years
62%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Long-Term Assets
$5.5B
CAGR 3-Years
47%
CAGR 5-Years
43%
CAGR 10-Years
32%
No Stocks Found

Grail Inc
Glance View

Market Cap
3.7B USD
Industry
Biotechnology

Grail Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Menlo Park, California and currently employs 1,370 full-time employees. The company went IPO on 2024-06-12. GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. The company is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.

GRAL Intrinsic Value
26.42 USD
Overvaluation 74%
Intrinsic Value
Price

See Also

What is Grail Inc's Other Long-Term Assets?
Other Long-Term Assets
11.1m USD

Based on the financial report for Dec 31, 2024, Grail Inc's Other Long-Term Assets amounts to 11.1m USD.

What is Grail Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 3Y
16%

Over the last year, the Other Long-Term Assets growth was -9%. The average annual Other Long-Term Assets growth rates for Grail Inc have been 16% over the past three years .

Back to Top